Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Tuesday, August 9, 2016

‘Toxic gases’ as targets for new medicines

These 'toxic gases' already have research proving helpfulness in stroke, but because we have fucking failures of stroke associations none have been written up into stroke protocols.
7 posts on carbon monoxide helping with neurogenesis, anti-inflammation and recovery.
6 posts on hydrogen sulfide helping with stroke prevention, reduction in stroke damage, protects stem cells and helps neurogenesis.
69 posts on nitric oxide for blood pressure and anti-inflammation.

You do realize how incompetent the stroke medical world has to be to not be doing anything with these to help stroke survivors?

‘Toxic gases’ as targets for new medicines

Gases once thought of only as environmental pollutants are now known to be produced by the body. They could potentially be used to develop drugs to treat diseases including heart failure and cancer.
Think of carbon monoxide (CO) and the chances are you will recall tragic stories of poisoning caused by a gas leak. Similarly, hydrogen sulphide (H2S) and nitrogen oxide (NO) were once known only for their negative impacts.
However, decades of research have revealed that while inhaling large volumes of these gases can be dangerous, they are produced in small quantities throughout the body. Not only are they not harmful in tiny doses, it turns out these gases – known as gasotransmitters – are essential to good health .
“Many diseases are caused by too much or too little of these gases,” says Andreas Papapetropoulos, Professor of Pharmacology at the University of Athens. “ Understanding their role in the body could have clinical applications .”
Professor Papapetropoulos is chair of COST Action BM1005 which has been working to identify new biological actions of gasotransmitters and translate this knowledge into gasotransmitter-related drugs. This could eventually allow doctors to restore balance where there is too much or too little of these gases.
More than 250 biologists and chemists from 23 countries have been developing methods to better measure gasotransmitters in cells and have been studying the mechanism of action of NO, CO and H2S. They have been developing and evaluating compounds that regulate the amount of gasotransmitters in the body, in collaboration with small and medium enterprises that have experience in this field.
“One area we have identified as having real potential is cardiovascular disease,” says Professor Papapetropoulos. “ H2S protects the heart against ischemia which occurs during a heart attack. NO also lowers blood pressure, which in turn reduces the risk of stroke.”
Prompting the body to release more of these protective gases in the heart could save lives. In the digestive system however, too much H2S is associated with colon cancer .
“Work done by network members and others has identified H2S-producing enzymes that are present in increased numbers in cancer. H2S inhibitors could be used to inhibit colon and breast cancer growth and this is a subject for future preclinical and clinical study,” Professor Papapetropoulos says.
More than 40 collaborative research papers have been published as a direct result of the gasotransmitters network and a wealth of knowledge, skills, expertise and reagents have been shared among participants.
The next step for this area of study is to explore how these three gasotransmitters interact with one another. With a growing network of young researchers dedicated to this field, Europe is well-placed to capitalise on a fast-growing field.
“We have made good progress in unifying this research area in Europe and we have also contributed on a global scale. This Action has helped to make Europe the pri-mary player in this field,” says Professor Papapetropoulos.

No comments:

Post a Comment